FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127481197> ?p ?o ?g. }

• W2127481197 endingPage "86" @default.
• W2127481197 startingPage "81" @default.
• W2127481197 abstract "Background Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mortality when compared with placebo in COPD. It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids (ICSs) plus long-acting β-agonists (LABAs). Methods We performed a retrospective cohort study using a National Health Service database of patients with COPD in Tayside, Scotland, between 2001 and 2010 that is linked with databases regarding hospital admissions, pharmacy prescriptions, and death registries. The impact of the addition of tiotropium (Tio) to ICS + LABA therapy on all-cause mortality, hospital admissions for respiratory disease, and emergency oral corticosteroid bursts was evaluated. Adjusted hazard ratios (HRs) were calculated by Cox regression after inclusion of the following covariates: cardiovascular and respiratory disease, diabetes, smoking, age, sex, and deprivation index. Results A total of 1,857 patients were given ICS + LABA + Tio, and 996 were given ICS + LABA. Mean follow-up was 4.65 years. The adjusted HR for all-cause mortality for ICS + LABA + Tio vs ICS + LABA was 0.65 (95% CI, 0.57-0.75; P < .001). Adjusted HRs for hospital admissions and oral corticosteroid bursts were 0.85 (95% CI, 0.73-0.99; P = .04) and 0.71 (95% CI, 0.63-0.80; P < .001), respectively. Conclusions The study suggests that the addition of tiotropium to ICSs and LABA therapy may confer benefits in reducing all-cause mortality, hospital admissions, and oral corticosteroid bursts in patients with COPD. Triple therapy is widely used in the real-life management of COPD, with only limited scientific support. The study supports the use of triple therapy in COPD and provides a platform for randomized controlled trials specifically addressing this topic. Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mortality when compared with placebo in COPD. It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids (ICSs) plus long-acting β-agonists (LABAs). We performed a retrospective cohort study using a National Health Service database of patients with COPD in Tayside, Scotland, between 2001 and 2010 that is linked with databases regarding hospital admissions, pharmacy prescriptions, and death registries. The impact of the addition of tiotropium (Tio) to ICS + LABA therapy on all-cause mortality, hospital admissions for respiratory disease, and emergency oral corticosteroid bursts was evaluated. Adjusted hazard ratios (HRs) were calculated by Cox regression after inclusion of the following covariates: cardiovascular and respiratory disease, diabetes, smoking, age, sex, and deprivation index. A total of 1,857 patients were given ICS + LABA + Tio, and 996 were given ICS + LABA. Mean follow-up was 4.65 years. The adjusted HR for all-cause mortality for ICS + LABA + Tio vs ICS + LABA was 0.65 (95% CI, 0.57-0.75; P < .001). Adjusted HRs for hospital admissions and oral corticosteroid bursts were 0.85 (95% CI, 0.73-0.99; P = .04) and 0.71 (95% CI, 0.63-0.80; P < .001), respectively. The study suggests that the addition of tiotropium to ICSs and LABA therapy may confer benefits in reducing all-cause mortality, hospital admissions, and oral corticosteroid bursts in patients with COPD. Triple therapy is widely used in the real-life management of COPD, with only limited scientific support. The study supports the use of triple therapy in COPD and provides a platform for randomized controlled trials specifically addressing this topic." @default.
• W2127481197 created "2016-06-24" @default.
• W2127481197 creator A5021959726 @default.
• W2127481197 creator A5028214076 @default.
• W2127481197 creator A5041732885 @default.
• W2127481197 creator A5043268741 @default.
• W2127481197 creator A5054519215 @default.
• W2127481197 creator A5060793550 @default.
• W2127481197 date "2012-01-01" @default.
• W2127481197 modified "2023-10-03" @default.
• W2127481197 title "The Impact of Tiotropium on Mortality and Exacerbations When Added to Inhaled Corticosteroids and Long-Acting β-Agonist Therapy in COPD" @default.
• W2127481197 cites W1920721512 @default.
• W2127481197 cites W1990651138 @default.
• W2127481197 cites W1996662684 @default.
• W2127481197 cites W2011384746 @default.
• W2127481197 cites W2025133561 @default.
• W2127481197 cites W2032171019 @default.
• W2127481197 cites W2104636056 @default.
• W2127481197 cites W2120629366 @default.
• W2127481197 cites W2121690051 @default.
• W2127481197 cites W2132565543 @default.
• W2127481197 cites W2134436842 @default.
• W2127481197 cites W2141034778 @default.
• W2127481197 cites W2142633372 @default.
• W2127481197 cites W2142724633 @default.
• W2127481197 cites W2150906543 @default.
• W2127481197 cites W2150978030 @default.
• W2127481197 cites W2157203303 @default.
• W2127481197 cites W2164405525 @default.
• W2127481197 cites W2168903081 @default.
• W2127481197 cites W2171652349 @default.
• W2127481197 doi "https://doi.org/10.1378/chest.11-0038" @default.
• W2127481197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21799028" @default.
• W2127481197 hasPublicationYear "2012" @default.
• W2127481197 type Work @default.
• W2127481197 sameAs 2127481197 @default.
• W2127481197 citedByCount "86" @default.
• W2127481197 countsByYear W21274811972012 @default.
• W2127481197 countsByYear W21274811972013 @default.
• W2127481197 countsByYear W21274811972014 @default.
• W2127481197 countsByYear W21274811972015 @default.
• W2127481197 countsByYear W21274811972016 @default.
• W2127481197 countsByYear W21274811972017 @default.
• W2127481197 countsByYear W21274811972018 @default.
• W2127481197 countsByYear W21274811972019 @default.
• W2127481197 countsByYear W21274811972020 @default.
• W2127481197 countsByYear W21274811972021 @default.
• W2127481197 countsByYear W21274811972022 @default.
• W2127481197 countsByYear W21274811972023 @default.
• W2127481197 crossrefType "journal-article" @default.
• W2127481197 hasAuthorship W2127481197A5021959726 @default.
• W2127481197 hasAuthorship W2127481197A5028214076 @default.
• W2127481197 hasAuthorship W2127481197A5041732885 @default.
• W2127481197 hasAuthorship W2127481197A5043268741 @default.
• W2127481197 hasAuthorship W2127481197A5054519215 @default.
• W2127481197 hasAuthorship W2127481197A5060793550 @default.
• W2127481197 hasConcept C126322002 @default.
• W2127481197 hasConcept C142724271 @default.
• W2127481197 hasConcept C167135981 @default.
• W2127481197 hasConcept C204787440 @default.
• W2127481197 hasConcept C207103383 @default.
• W2127481197 hasConcept C2426938 @default.
• W2127481197 hasConcept C27081682 @default.
• W2127481197 hasConcept C2776780178 @default.
• W2127481197 hasConcept C2776804153 @default.
• W2127481197 hasConcept C2777014857 @default.
• W2127481197 hasConcept C2779028295 @default.
• W2127481197 hasConcept C44249647 @default.
• W2127481197 hasConcept C71924100 @default.
• W2127481197 hasConcept C98274493 @default.
• W2127481197 hasConceptScore W2127481197C126322002 @default.
• W2127481197 hasConceptScore W2127481197C142724271 @default.
• W2127481197 hasConceptScore W2127481197C167135981 @default.
• W2127481197 hasConceptScore W2127481197C204787440 @default.
• W2127481197 hasConceptScore W2127481197C207103383 @default.
• W2127481197 hasConceptScore W2127481197C2426938 @default.
• W2127481197 hasConceptScore W2127481197C27081682 @default.
• W2127481197 hasConceptScore W2127481197C2776780178 @default.
• W2127481197 hasConceptScore W2127481197C2776804153 @default.
• W2127481197 hasConceptScore W2127481197C2777014857 @default.
• W2127481197 hasConceptScore W2127481197C2779028295 @default.
• W2127481197 hasConceptScore W2127481197C44249647 @default.
• W2127481197 hasConceptScore W2127481197C71924100 @default.
• W2127481197 hasConceptScore W2127481197C98274493 @default.
• W2127481197 hasIssue "1" @default.
• W2127481197 hasLocation W21274811971 @default.
• W2127481197 hasLocation W21274811972 @default.
• W2127481197 hasOpenAccess W2127481197 @default.
• W2127481197 hasPrimaryLocation W21274811971 @default.
• W2127481197 hasRelatedWork W1989631589 @default.
• W2127481197 hasRelatedWork W2100738224 @default.
• W2127481197 hasRelatedWork W2109156359 @default.
• W2127481197 hasRelatedWork W2165653930 @default.
• W2127481197 hasRelatedWork W2518136641 @default.
• W2127481197 hasRelatedWork W2944506658 @default.
• W2127481197 hasRelatedWork W3175747749 @default.
• W2127481197 hasRelatedWork W3177022460 @default.
• W2127481197 hasRelatedWork W4205451730 @default.

• next